Vertex Pharmaceuticals (VRTX)’s Insider Amit Sachdev Sold 2,155 Shares; Rockwell Automation Inc. (ROK) Had 4 Analysts Last Week

Among 29 analysts covering Rockwell Automation (NYSE:ROK), 4 have Buy rating, 3 Sell and 22 Hold. Therefore 14% are positive. Rockwell Automation had 65 analyst reports since September 9, 2015 according to SRatingsIntel. The rating was initiated by Citigroup with “Neutral” on Thursday, January 21. On Monday, October 2 the stock rating was maintained by Morgan Stanley with “Equal-Weight”. Berenberg initiated Rockwell Automation Inc. (NYSE:ROK) rating on Monday, October 3. Berenberg has “Sell” rating and $110 target. The stock of Rockwell Automation Inc. (NYSE:ROK) has “Neutral” rating given on Monday, October 10 by . The stock of Rockwell Automation Inc. (NYSE:ROK) earned “Neutral” rating by Credit Suisse on Wednesday, August 23. The stock of Rockwell Automation Inc. (NYSE:ROK) earned “Hold” rating by Oppenheimer on Thursday, July 27. The stock of Rockwell Automation Inc. (NYSE:ROK) earned “Equal-Weight” rating by Morgan Stanley on Thursday, January 25. The firm has “Equal-Weight” rating given on Monday, October 5 by Barclays Capital. The stock of Rockwell Automation Inc. (NYSE:ROK) earned “Hold” rating by HSBC on Friday, October 7. Citigroup maintained the stock with “Neutral” rating in Thursday, January 25 report. See Rockwell Automation Inc. (NYSE:ROK) latest ratings:

15/02/2018 Broker: Stifel Nicolaus Rating: Hold New Target: $188.0 Maintain
15/02/2018 Broker: Barclays Capital Rating: Equal-Weight New Target: $200 Initiates Coverage On
25/01/2018 Broker: Stifel Nicolaus Rating: Hold New Target: $214.0 Maintain
25/01/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Neutral Old Target: $182 New Target: $190 Maintain
25/01/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $194 New Target: $206 Maintain
25/01/2018 Broker: Wells Fargo Old Rating: Market Perform New Rating: Market Perform Old Target: $190 New Target: $200 Maintain
25/01/2018 Broker: Citigroup Old Rating: Neutral New Rating: Neutral Old Target: $214 New Target: $209 Maintain
23/01/2018 Broker: UBS Rating: Buy Initiates Coverage On
20/12/2017 Broker: Daiwa Securities Rating: Neutral New Target: $199 Initiates Coverage On
10/12/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $198.0 Maintain

Vertex Pharmaceuticals Inc Ma EVP – CRO and an insider Amit Sachdev lately sold 2,155 company shares having a value of $366,350 at an avg market stock price per share of $170.0. Amit is trying to silently decrease his company’s share, same as he did in the last 30 days. He unloaded another 37,401 shares worth $5,985,661 USD. This transaction was pretty significant, so clearly it won’t go undiscovered. Presently, he has a total of 59,759 shares or 0.02% of Vertex Pharmaceuticals Inc Ma’s total market cap (Market Capitalization is a measurement of business value based on share price and number of shares outstanding). Dated February 28, 2018, this giant deal by Amit Sachdev was unveiled in a public form that was filed with the U.S. Security and Exchange Commission. It is freely available for review here.

Vertex Pharmaceuticals Incorporated discovers, develops, makes, and commercializes medicines for serious diseases. The company has market cap of $41.93 billion. The firm focuses on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs. It has a 158.94 P/E ratio. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene.

Investors sentiment increased to 1.62 in Q3 2017. Its up 0.11, from 1.51 in 2017Q2. It increased, as 32 investors sold Vertex Pharmaceuticals Incorporated shares while 151 reduced holdings. 79 funds opened positions while 217 raised stakes. 231.42 million shares or 0.04% more from 231.33 million shares in 2017Q2 were reported. Moreover, Polar Cap Llp has 0.2% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 116,500 shares. New York-based Focused Wealth Mgmt has invested 0% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). D E Shaw & invested in 0.08% or 324,089 shares. Alpha Windward Limited Com reported 600 shares. Us State Bank De owns 0% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 7,197 shares. Rnc Cap Limited Liability Company holds 0.02% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) or 1,743 shares. Dimensional Fund Advisors Limited Partnership reported 296,881 shares. Quantitative Systematic Strategies Ltd Liability Co reported 2,480 shares or 0.1% of all its holdings. State Common Retirement Fund holds 0.16% or 822,531 shares. Shine Invest Advisory Svcs Inc invested 0% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Wealth Enhancement Advisory Ltd Limited Liability Company has invested 0.07% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Oakmont Ltd has 2,000 shares. Aqr Mgmt Limited Liability Company accumulated 1.89M shares. Proshare Advsr, Maryland-based fund reported 217,305 shares. Columbus Circle holds 1.17% or 452,645 shares.

Analysts await Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to report earnings on April, 26. They expect $0.27 EPS, up 107.69% or $0.14 from last year’s $0.13 per share. VRTX’s profit will be $68.55M for 152.90 P/E if the $0.27 EPS becomes a reality. After $0.32 actual EPS reported by Vertex Pharmaceuticals Incorporated for the previous quarter, Wall Street now forecasts -15.63% negative EPS growth.

Since August 31, 2017, it had 0 insider buys, and 42 insider sales for $117.99 million activity. Another trade for 5,122 shares valued at $772,493 was sold by Chodakewitz Jeffrey. Another trade for 15,085 shares valued at $2.56M was sold by Sachdev Amit. On Monday, February 5 the insider Silva Paul M sold $342,142. 2,125 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares with value of $324,976 were sold by Parini Michael. ALTSHULER DAVID also sold $287,360 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares. 125,000 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares with value of $17.67M were sold by LEIDEN JEFFREY M. 81,290 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares with value of $11.77 million were sold by Arbuckle Stuart A.

Among 30 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 26 have Buy rating, 0 Sell and 4 Hold. Therefore 87% are positive. Vertex Pharmaceuticals has $212.0 highest and $85.0 lowest target. $180.24’s average target is 9.15% above currents $165.135 stock price. Vertex Pharmaceuticals had 97 analyst reports since July 31, 2015 according to SRatingsIntel. On Thursday, April 28 the stock rating was maintained by RBC Capital Markets with “Outperform”. Leerink Swann maintained it with “Outperform” rating and $128 target in Tuesday, March 8 report. Leerink Swann maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Tuesday, September 26 with “Buy” rating. The company was downgraded on Thursday, April 28 by Goldman Sachs. The rating was upgraded by Argus Research on Monday, September 28 to “Buy”. Credit Suisse initiated the shares of VRTX in report on Wednesday, January 20 with “Outperform” rating. The company was maintained on Wednesday, October 5 by Jefferies. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has “Hold” rating given on Wednesday, July 5 by Cowen & Co. The stock has “Buy” rating by Jefferies on Thursday, September 29. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Overweight” rating by Barclays Capital on Monday, September 14.

The stock decreased 0.45% or $0.745 during the last trading session, reaching $165.135. About 108,732 shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 45.69% since February 28, 2017 and is uptrending. It has outperformed by 28.99% the S&P500.

Rockwell Automation Inc. provides industrial automation and information solutions worldwide. The company has market cap of $23.55 billion. It operates in two divisions, Architecture & Software; and Control Products & Solutions. It has a 63.67 P/E ratio. The Architecture & Software segment provides control platforms, including controllers, electronic operator interface devices, electronic input/output devices, communication and networking products, and industrial computers that perform multiple control disciplines and monitoring of applications, such as discrete, batch and continuous process, drives control, motion control, and machine safety control.

Since September 12, 2017, it had 0 buys, and 13 selling transactions for $28.06 million activity. 28,800 shares were sold by Schmitt Susan, worth $5.80 million. $831,996 worth of Rockwell Automation Inc. (NYSE:ROK) shares were sold by MILLER JOHN M. Moret Blake D. sold $965,638 worth of stock. Murphy Robert B also sold $139,200 worth of Rockwell Automation Inc. (NYSE:ROK) on Thursday, February 1. MCDERMOTT JOHN P had sold 1,950 shares worth $364,813 on Friday, February 16. Kulaszewicz Frank C also sold $7.66M worth of Rockwell Automation Inc. (NYSE:ROK) shares. DORGAN DAVID M also sold $2.11M worth of Rockwell Automation Inc. (NYSE:ROK) shares.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: